The FDA has recently approved Skyla, a new hormone-releasing system that is placed in the uterus for the prevention of pregnancy. Click here to view the Press Release in PDF Format!

The Academy of Oncology Nurse Navigators white paper, "Assessing the Creative Application and Usefulness of NSider: A Tactical Tool for the Oncology Nurse Navigator" was published in the journal, The Oncology Nurse-APN/NP.

Researchers discover DNA 'repair' enzyme that could enhance cancer treatmentsSmarter America via Fox NewsResearchers have discovered an enzyme responsible for repairing single DNA strands damaged through cell division, which they hope will someday lead to better treatments for cancer, Parkinson's and Alzheimer's disease. As we grow, the number of cells in our body must grow as well. In order to multiply, a cell's DNA must divide into two strands, creating two identical templates for the genomes of the "daughter" cells.

Researchers explore genetic links between nicotine, cancer using 'next-generation sequencing'Virginia Polytechnic Institute via Medical XpressNicotine is the addictive chemical found in cigarettes, but researchers believe that it could have more influence than previously realized on the underlying genetics of cancer, according to a recently published study in the journal PLOS One. Tobacco smoke contains many chemicals, including nicotine, but nicotine stands out because of its widely accepted connection to cancer, especially lung cancer.

Unraveling genetic networksAmerican Institute of Physics via Phys.Org If genes are the currency of life, then the whole economies are genetic networks, which include genes as well as the complex webs of interactions and interconnections between them. Genetic networks are integrally important to the proper development and functioning of an organism, just as genes are, but they tend to be far more complex and difficult to understand.

New compound could combat castration-resistant prostate cancerFierceBiotechResearchers at Sanford-Burnham Medical Research Institute may have hit on the next big thing in prostate cancer treatment. They've developed a compound called SMIP004 that works by zeroing in on prostate cancer cells and compromising their ability to withstand environmental stress — a trademark of cancer cells. Prostate cancer is the second most common cancer and the second leading cause of cancer-related deaths among men in the United States.

Personalized risk calculator for women's cancersMedical News TodayResearchers have discovered a new way of predicting whether a woman is at risk of cancer of the breast, ovaries or uterus, according to a study published in the journal PLoS Medicine. Researchers from the National Cancer Institute and colleagues from other U.S. medical institutes developed "absolute risk prediction models" that could help women predict their chances of developing breast, ovarian or endometrial cancer.

Could sleeping stem cells hold key to treatment of aggressive blood cancer?ScienceDailyScientists studying an aggressive form of leukemia have discovered that rather than displacing healthy stem cells in the bone marrow as previously believed, the cancer is putting them to sleep to prevent them forming new blood cells. The finding offers the potential that these stem cells could somehow be turned back on, offering a new form of treatment for the condition, called Acute Myeloid Leukemia.

Stem cell success: Urine used to create teethMedical News TodayStem cell research is opening up the way for new teeth "grown" from an unlikely source — human urine. Chinese researchers describe how stem cells derived from urine could be used to generate solid organs and tissues, including teeth. Their study is published in the open-access journal Cell Regeneration. The researchers hope the technique might one day help provide new, tailor-made teeth for dental patients.

Top 5 technology trends in the global medical devices marketHIT Consultant The new 2013 Frost & Sullivan outlook study provides projections for the global medical devices market. The Research identifies market sectors and subsectors poised for expansion; discusses key opportunities in emerging markets; identifies the four Rs in the medical device spectrum; and covers strategies for success in the new market paradigm. Home care, structural heart, robotic assistance, infection control tools and neurology devices were identified as the top five growth sectors in the medical device market.

70 percent of medical errors can be blamed on technology and equipment failuresMedical DailyAdvances in technology have allowed us to do things once thought impossible. However, working smarter may lead to unforeseen errors thanks to malfunctioning technology or other related issues. How many errors occur that lead to adverse events, and how can medial professional hope to avoid these errors if they are coming from useful equipment?

White House touts slow increase in health care costsUSA TodayPersonal healthcare costs rose in the 12 months ending in May at the slowest rate in the last 50 years, as spending on hospital and nursing home services declined, the White House announced. Personal consumption spending rose 1.1 percent, Alan Krueger, chairman of the White House Council of Economic Advisers, said.

Could the future of healthcare mean no waits in hospitals?Fast CompanyAs medical treatment is impacted by technology, consumerization and the mobile revolution, we may see a world where your doctor already knows why you're sick and can treat you over the phone — leaving the hospitals for the true emergencies.

Are 90 percent of FDA drugs approved in last 30 years no more effective than existing drugs?ForbesDonald W. Light of the School of Public Health, University of Medicine & Dentistry of New Jersey, states the following: "A forthcoming article for the special issue of the Journal of Law, Medicine and Ethics, edited by Marc Rodwin and supported by the Edmond J. Safra Center for Ethics, presents evidence that about 90 percent of all new drugs approved by the FDA over the past 30 years are little or no more effective for patients than existing drugs. All of them may be better than indirect measures or placebos, but most are no better for patients than previous drugs approved as better against these measures."

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!